

Tibor Szarvas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5420862/publications.pdf>

Version: 2024-02-01

124
papers

2,410
citations

172386

29
h-index

276775

41
g-index

153
all docs

153
docs citations

153
times ranked

3421
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical, prognostic, and therapeutic aspects of urachal carcinoma—A comprehensive review with meta-analysis of 1,010 cases. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 388-398.	0.8	119
2	Matrix metalloproteinases and their clinical relevance in urinary bladder cancer. <i>Nature Reviews Urology</i> , 2011, 8, 241-254.	1.9	96
3	Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. <i>Cancer Science</i> , 2010, 101, 1300-1308.	1.7	92
4	The long noncoding RNA HOTAIR has tissue and cell type-dependent effects on HOX gene expression and phenotype of urothelial cancer cells. <i>Molecular Cancer</i> , 2015, 14, 108.	7.9	72
5	Direct upstream integration of biogasoline production into current light straight run naphtha petrorefinery processes. <i>Nature Energy</i> , 2018, 3, 969-977.	19.8	58
6	Inhibitory Role of the Small Leucine-Rich Proteoglycan Biglycan in Bladder Cancer. <i>PLoS ONE</i> , 2013, 8, e80084.	1.1	49
7	Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancer. <i>Human Pathology</i> , 2014, 45, 674-682.	1.1	49
8	The prognostic value of cadherin switch in bladder cancer. <i>Oncology Reports</i> , 2010, 23, 1125-32.	1.2	48
9	Deletion analysis of tumor and urinary DNA to detect bladder cancer: urine supernatant versus urine sediment. <i>Oncology Reports</i> , 2007, 18, 405-9.	1.2	47
10	High Prevalence of Liddle Syndrome Phenotype Among Hypertensive US Veterans in Northwest Louisiana. <i>Journal of Clinical Hypertension</i> , 2010, 12, 856-860.	1.0	45
11	Mutations of KRAS, NRAS, BRAF, EGFR, and PIK3CA genes in urachal carcinoma: Occurrence and prognostic significance. <i>Oncotarget</i> , 2016, 7, 39293-39301.	0.8	45
12	Angiogenic Switch of Angiotensin-Tie2 System and Its Prognostic Value in Bladder Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 8253-8262.	3.2	44
13	External Validation of a Multiplex Urinary Protein Panel for the Detection of Bladder Cancer in a Multicenter Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1804-1812.	1.1	44
14	Pathogenic and targetable genetic alterations in 70 urachal adenocarcinomas. <i>International Journal of Cancer</i> , 2018, 143, 1764-1773.	2.3	44
15	Validation of Circulating MMP-7 Level as an Independent Prognostic Marker of Poor Survival in Urinary Bladder Cancer. <i>Pathology and Oncology Research</i> , 2011, 17, 325-332.	0.9	43
16	Prospective evaluation of diffusion-weighted MRI of the bladder as a biomarker for prediction of bladder cancer aggressiveness. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 1166-1171.	0.8	42
17	High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 49, 385-389.	3.3	41
18	Serum endostatin levels correlate with enhanced extracellular matrix degradation and poor patients' prognosis in bladder cancer. <i>International Journal of Cancer</i> , 2012, 130, 2922-2929.	2.3	40

#	ARTICLE	IF	CITATIONS
19	Elevated serum matrix metalloproteinase 7 levels predict poor prognosis after radical prostatectomy. <i>International Journal of Cancer</i> , 2011, 128, 1486-1492.	2.3	39
20	Soluble syndecan-1 (SDC1) serum level as an independent preoperative predictor of cancer-specific survival in prostate cancer. <i>Prostate</i> , 2016, 76, 977-985.	1.2	39
21	Diagnostic and prognostic value of long noncoding RNAs as biomarkers in urothelial carcinoma. <i>PLoS ONE</i> , 2017, 12, e0176287.	1.1	39
22	Volume estimation in dialysis patients: The concordance of brain-type natriuretic peptide measurements and bioimpedance values. <i>Hemodialysis International</i> , 2013, 17, 406-412.	0.4	38
23	Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data. <i>Disease Markers</i> , 2018, 2018, 1-21.	0.6	38
24	Serum Levels of Angiogenic Factors and their Prognostic Relevance in Bladder Cancer. <i>Pathology and Oncology Research</i> , 2009, 15, 193-201.	0.9	32
25	Urachal Carcinoma of the Bladder: Impact of Clinical and Immunohistochemical Parameters on Prognosis. <i>Journal of Urology</i> , 2016, 195, 1690-1696.	0.2	32
26	Circulating and tissue IMP3 levels are correlated with poor survival in renal cell carcinoma. <i>International Journal of Cancer</i> , 2019, 145, 531-539.	2.3	32
27	The Impact of the Receptor of Hyaluronan-Mediated Motility (RHAMM) on Human Urothelial Transitional Cell Cancer of the Bladder. <i>PLoS ONE</i> , 2013, 8, e75681.	1.1	32
28	Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. <i>Pathology and Oncology Research</i> , 2007, 13, 187-194.	0.9	31
29	High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer. <i>BJU International</i> , 2012, 110, E308-17.	1.3	31
30	Dialysis Patients' Fluid Overload, Antihypertensive Medications, and Obesity. <i>ASAIO Journal</i> , 2011, 57, 511-515.	0.9	30
31	Quantitative Apparent Diffusion Coefficient Measurements Obtained by 3-Tesla MRI Are Correlated with Biomarkers of Bladder Cancer Proliferative Activity. <i>PLoS ONE</i> , 2014, 9, e106866.	1.1	29
32	The presence of human papillomavirus 16 in neural structures and vascular endothelial cells. <i>Virology</i> , 2006, 348, 289-296.	1.1	28
33	Urinary matrix metalloproteinase-7 level is associated with the presence of metastasis in bladder cancer. <i>BJU International</i> , 2011, 107, 1069-1073.	1.3	28
34	Expression of GLUT1 is associated with increasing grade of malignancy in non-invasive and invasive urothelial carcinomas of the bladder. <i>Oncology Letters</i> , 2011, 2, 1149-1153.	0.8	27
35	Retroperitoneal Versus Transperitoneal Robotic Partial Nephrectomy: A Multicenter Matched-pair Analysis. <i>European Urology Focus</i> , 2021, 7, 1363-1370.	1.6	26
36	Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7431.	1.8	25

#	ARTICLE	IF	CITATIONS
37	Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer. <i>Cancers</i> , 2020, 12, 353.	1.7	24
38	Deletion analysis of tumor and urinary DNA to detect bladder cancer: Urine supernatant versus urine sediment. <i>Oncology Reports</i> , 0, , .	1.2	23
39	Prognostic impact of plasminogen activator inhibitor type 1 expression in bladder cancer. <i>Cancer</i> , 2010, 116, 4502-4512.	2.0	23
40	A contemporary experience of open aortic reconstruction in patients with chronic atherosclerotic occlusion of the abdominal aorta. <i>Journal of Vascular Surgery</i> , 2010, 52, 1164-1172.	0.6	23
41	Radioisotopic investigation of the oleic acid-1-14C HDO reaction pathways on sulfided Mo/P/Al ₂ O ₃ and NiW/Al ₂ O ₃ catalysts. <i>Applied Catalysis B: Environmental</i> , 2015, 165, 245-252.	10.8	23
42	Why are upper tract urothelial carcinoma two different diseases?. <i>Translational Andrology and Urology</i> , 2016, 5, 636-647.	0.6	23
43	Circulating syndecan-1 is associated with chemotherapy-resistance in castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 312.e9-312.e15.	0.8	23
44	Prognostic value of tissue and circulating levels of IMP3 in prostate cancer. <i>International Journal of Cancer</i> , 2014, 135, 1596-1604.	2.3	22
45	Prognostic effect of serum and tissue YKL-40 levels in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 663-669.	0.8	22
46	Validation of survivin and HMGA2 as biomarkers for cisplatin resistance in bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 810.e7-810.e15.	0.8	22
47	Comprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancer. <i>BJU International</i> , 2021, 127, 44-55.	1.3	22
48	A Prospective Evaluation of Pain Associated With Stone Passage, Stents, and Stent Removal Using a Visual Analog Scale. <i>Urology</i> , 2013, 82, 521-525.	0.5	20
49	Truncated Isoforms of lncRNA ANRIL Are Overexpressed in Bladder Cancer, But Do Not Contribute to Repression of INK4 Tumor Suppressors. <i>Non-coding RNA</i> , 2015, 1, 266-284.	1.3	20
50	Renal cell carcinoma and tumour thrombus in the inferior vena cava: clinical outcome of 98 consecutive patients and the prognostic value of preoperative parameters. <i>World Journal of Urology</i> , 2015, 33, 1541-1552.	1.2	17
51	Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer. <i>Pathology International</i> , 2017, 67, 597-601.	0.6	17
52	High Serum PD-L1 Levels Are Associated with Poor Survival in Urothelial Cancer Patients Treated with Chemotherapy and Immune Checkpoint Inhibitor Therapy. <i>Cancers</i> , 2021, 13, 2548.	1.7	17
53	Serum Chromogranin A as a Complementary Marker for the Prediction of Prostate Cancer-Specific Survival. <i>Pathology and Oncology Research</i> , 2017, 23, 643-650.	0.9	16
54	Validation of the diagnostic and prognostic relevance of serum MMP-7 levels in renal cell cancer by using a novel automated fluorescent immunoassay method. <i>International Urology and Nephrology</i> , 2016, 48, 355-361.	0.6	15

#	ARTICLE	IF	CITATIONS
55	Urachal cancer – current concepts of a rare cancer. <i>Der Pathologe</i> , 2019, 40, 31-39.	0.7	15
56	Diuretics and Bioimpedance – Measured Fluid Spaces in Hypertensive Patients. <i>Journal of Clinical Hypertension</i> , 2014, 16, 895-899.	1.0	14
57	Circulating and Tissue Expression Levels of YKL-40 in Renal Cell Cancer. <i>Journal of Urology</i> , 2016, 195, 1120-1125.	0.2	13
58	Clinical Utility of Potassium-Sparing Diuretics to Maintain Normal Serum Potassium in Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2017, 37, 63-69.	1.1	13
59	Circulating Angiostatin, bFGF, and Tie2/TEK Levels and Their Prognostic Impact in Bladder Cancer. <i>Urology</i> , 2012, 80, 737.e13-737.e18.	0.5	12
60	The safety and efficacy of bedside removal of tunneled hemodialysis catheters by nephrology trainees. <i>Renal Failure</i> , 2013, 35, 1264-1268.	0.8	12
61	Clinical Sequencing-guided Therapy of Urachal Carcinoma: New Perspective for a Rare Cancer. <i>European Urology</i> , 2016, 70, 776-777.	0.9	12
62	The Role of YKL-40 in Predicting Resistance to Docetaxel Chemotherapy in Prostate Cancer. <i>Urologia Internationalis</i> , 2018, 101, 65-73.	0.6	12
63	Urachal Cancer in Germany and the USA: An RKI/SEER Population-Based Comparison Study. <i>Urologia Internationalis</i> , 2020, 104, 803-809.	0.6	12
64	Sulfur exchange capacity and thiophene hydrodesulfurization activity of sulfided molybdena-alumina catalysts promoted by nickel. <i>Catalysis Today</i> , 2012, 181, 148-155.	2.2	10
65	STIP1 Tissue Expression Is Associated with Survival in Chemotherapy-Treated Bladder Cancer Patients. <i>Pathology and Oncology Research</i> , 2020, 26, 1243-1249.	0.9	10
66	Prevalence of APC and PTEN Alterations in Urachal Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 2773-2781.	0.9	10
67	Evaluation of HER2 expression in urothelial carcinoma cells as a biomarker for circulating tumor cells. <i>Cytometry Part B - Clinical Cytometry</i> , 2020, 98, 355-367.	0.7	10
68	A new technological approach in diagnostic pathology: mass spectrometry imaging-based metabolomics for biomarker detection in urachal cancer. <i>Laboratory Investigation</i> , 2021, 101, 1281-1288.	1.7	10
69	Regional Differences in Nonadherence to Dialysis Among Southern Dialysis Patients: A Comparative Cross-Sectional Study to the Dialysis Outcomes and Practice Patterns Study. <i>American Journal of the Medical Sciences</i> , 2010, 339, 516-518.	0.4	8
70	Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 728.e13-728.e24.	0.8	8
71	MMP-7 Serum and Tissue Levels Are Associated with Poor Survival in Platinum-Treated Bladder Cancer Patients. <i>Diagnostics</i> , 2021, 11, 48.	1.3	8
72	Schnellverfahren zur Gasanalyse des Radiokohlenstoffes unter Atmosphärendruck. <i>Mikrochimica Acta</i> , 1963, 51, 139-150.	2.5	7

#	ARTICLE	IF	CITATIONS
73	Correlation of Pathological and Cytological-Cytometric Grading of Transitional Cell Carcinoma of the Urinary Tract. <i>Urologia Internationalis</i> , 2011, 86, 36-40.	0.6	7
74	Matrix metalloproteinase 7, soluble Fas and Fas ligand serum levels for predicting docetaxel resistance and survival in castration-resistant prostate cancer. <i>BJU International</i> , 2018, 122, 695-704.	1.3	7
75	The Prognostic Value of Cytokeratin and Extracellular Collagen Expression in Urinary Bladder Cancer. <i>Current Molecular Medicine</i> , 2022, 22, 941-949.	0.6	7
76	Low socioeconomic position is a risk factor for delay to treatment and mortality of testicular cancer patients in Hungary, a prospective study. <i>BMC Public Health</i> , 2021, 21, 1707.	1.2	7
77	Gas analysis of tritium in the form of ethane. <i>The International Journal of Applied Radiation and Isotopes</i> , 1963, 14, 197-203.	0.7	6
78	Sulfur uptake determination on Ni containing molybdena-alumina samples by radioisotope tracer technique. <i>Applied Radiation and Isotopes</i> , 2008, 66, 1190-1195.	0.7	6
79	Urinary Protein Markers for the Detection and Prognostication of Urothelial Carcinoma. <i>Methods in Molecular Biology</i> , 2018, 1655, 251-273.	0.4	6
80	The particular characteristics of the active sites of MoS ₂ , WS ₂ catalysts in thiophene hydrodesulfurization. <i>Reaction Kinetics, Mechanisms and Catalysis</i> , 2018, 124, 61-74.	0.8	6
81	Syndecan-1 Promotes Hepatocyte-Like Differentiation of Hepatoma Cells Targeting Ets-1 and AP-1. <i>Biomolecules</i> , 2020, 10, 1356.	1.8	6
82	Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer Patients. <i>Diagnostics</i> , 2020, 10, 864.	1.3	6
83	The prognostic value of serum MMP-7 levels in prostate cancer patients who received docetaxel, abiraterone, or enzalutamide therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 296.e11-296.e19.	0.8	6
84	A qPCR-based method for molecular subtype classification of urinary bladder cancer stromal gene expressions show higher prognostic values than intrinsic tumor genes. <i>International Journal of Cancer</i> , 2021, , .	2.3	6
85	The effect of ambient temperature and humidity on interdialytic weight gains in end-stage renal disease patients on maintenance hemodialysis. <i>International Urology and Nephrology</i> , 2016, 48, 1171-1176.	0.6	5
86	ERG expression can predict the outcome of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 289.e1-289.e9.	0.8	5
87	Molecular Characterization of Mullerian Tumors of the Urinary Tract. <i>Genes</i> , 2021, 12, 880.	1.0	5
88	The determination of sulphur-35 in organic compounds by gas counting as hydrogen sulphide. <i>The International Journal of Applied Radiation and Isotopes</i> , 1967, 18, 457-463.	0.7	4
89	Response of Hepatic Stellate Cells to TGFβ1 Differs from the Response of Myofibroblasts. Decorin Protects against the Action of Growth Factor. <i>Pathology and Oncology Research</i> , 2017, 23, 287-294.	0.9	4
90	Nuclear Localization of Robo is Associated with Better Survival in Bladder Cancer. <i>Pathology and Oncology Research</i> , 2020, 26, 253-261.	0.9	4

#	ARTICLE	IF	CITATIONS
91	Editorial Comment from Dr Szarvas and Dr Reis to Clinicopathological features of malignant urachal tumor: A hospital-based cancer registry data in Japan. <i>International Journal of Urology</i> , 2020, 27, 163-164.	0.5	4
92	Multiple Docetaxel Retreatments Without Prednisone for Metastatic Castration-Resistant Prostate Cancer in the Docetaxel-Only Era: Effects on PSA Kinetics and Survival. <i>Advances in Therapy</i> , 2021, 38, 3831-3841.	1.3	4
93	Integrated workflow for urinary prostate specific antigen N-glycosylation analysis using sdAb partitioning and downstream capillary electrophoresis separation. <i>Analytica Chimica Acta</i> , 2021, 1184, 338892.	2.6	4
94	Prostate specific membrane antigen-radio guided surgery using Cerenkov luminescence imaging—utilization of a short-pass filter to reduce technical pitfalls. <i>Translational Andrology and Urology</i> , 2021, 10, 3972-3985.	0.6	4
95	Current State of ERG as Biomarker in Prostatic Adenocarcinoma. <i>Current Cancer Drug Targets</i> , 2015, 15, 643-651.	0.8	4
96	Elevated Pre-Treatment Serum MMP-7 Levels Are Associated with the Presence of Metastasis and Poor Survival in Upper Tract Urothelial Carcinoma. <i>Biomedicines</i> , 2022, 10, 698.	1.4	4
97	Uric Acid Control in Advanced Chronic Kidney Disease in a Southeastern US Urban Cohort. <i>Southern Medical Journal</i> , 2018, 111, 549-555.	0.3	3
98	Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2022, 26, 1332-1337.	1.6	3
99	Comparative analysis of Bricker versus Wallace ureteroenteric anastomosis and identification of predictors for postoperative ureteroenteric stricture. <i>Langenbeck's Archives of Surgery</i> , 2022, 407, 1233-1240.	0.8	3
100	Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified <i>ALCAM</i> as marker of resistance in castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 0, .	2.3	3
101	Anwendung von Mikromethoden in der organischen Isotopengasanalyse. <i>Mikrochimica Acta</i> , 1970, 58, 900-904.	2.5	2
102	1416 TISSUE MMP-7 EXPRESSION PREDICTS SURVIVAL IN BLADDER CANCER PATIENTS TREATED WITH CISPLATIN-BASED CHEMOTHERAPY. <i>Journal of Urology</i> , 2012, 187, .	0.2	2
103	Claros System: A Rapid Microfluidics-Based Point-of-Care System for Quantitative Prostate Specific Antigen Analysis from Finger-Stick Blood. <i>Advances in Therapy</i> , 2019, 36, 916-922.	1.3	2
104	COVID-19 research: promising tracks leading to uro-oncology. <i>International Urology and Nephrology</i> , 2020, 52, 995-997.	0.6	2
105	Neoadjuvant cisplatin-based chemotherapy in "primary" and "secondary" muscle-invasive bladder cancer—is it a surrogate for molecular subtypes?. <i>Translational Cancer Research</i> , 2019, 8, S176-S179.	0.4	2
106	Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer. <i>Genes</i> , 2022, 13, 422.	1.0	2
107	Response to: Absence of GNAS and BRAF mutations but presence of KRAS mutation in urachal adenocarcinoma. <i>Pathology</i> , 2017, 49, 561-562.	0.3	1
108	Molecular and therapeutic aspects of advanced urachal cancer. <i>European Urology Supplements</i> , 2017, 16, e2840.	0.1	1

#	ARTICLE	IF	CITATIONS
109	Comparative proteome analysis identified NAMPT as a potential serum marker for the prediction of docetaxel-resistance in prostate cancer. <i>European Urology Supplements</i> , 2019, 18, e482.	0.1	1
110	Serum and tissue syndecan-1 levels in renal cell carcinoma. <i>Translational Andrology and Urology</i> , 2020, 9, 1167-1176.	0.6	1
111	Experimental proof of thiophene hydrodesulfurization reaction steps by isotope (¹⁴ C) labeled thiophene. <i>Reaction Kinetics, Mechanisms and Catalysis</i> , 2021, 134, 697-710.	0.8	1
112	High-soluble CGA levels are associated with poor survival in bladder cancer. <i>Endocrine Connections</i> , 2019, 8, 625-633.	0.8	1
113	Clinical outcome and quality of life in octogenarian patients with muscle-invasive urothelial carcinoma of the bladder treated with radical cystectomy or transurethral resection of the bladder tumor: a retrospective analysis of 143 patients. <i>International Urology and Nephrology</i> , 2022, 54, 71-79.	0.6	1
114	Major Complications after Male Anti-Incontinence Procedures: Predisposing Factors, Management and Prevention. <i>Urology Journal</i> , 2020, 18, 92-96.	0.3	1
115	The Conversion of Butadiene on Thiophene Hydrodesulfurization Catalysts. <i>Topics in Catalysis</i> , 2012, 55, 792-799.	1.3	0
116	Reply by the Authors. <i>Urology</i> , 2013, 82, 1192-1193.	0.5	0
117	Editorial Comment to Characterization and risk stratification of prostate cancer in patients undergoing radical cystoprostatectomy. <i>International Journal of Urology</i> , 2013, 20, 872-872.	0.5	0
118	Editorial Comment from D Szarvas to Functional polymorphisms in the matrix metalloproteinase genes and their association with bladder cancer risk and recurrence: A mini-review. <i>International Journal of Urology</i> , 2014, 21, 753-753.	0.5	0
119	Re: Association of Oncofetal Protein Expression with Clinical Outcomes in Patients with Urothelial Carcinoma of the Bladder. <i>Journal of Urology</i> , 2014, 192, 617-618.	0.2	0
120	Diagnostic and prognostic value of long non-coding RNA expression in urothelial carcinoma. <i>European Journal of Cancer</i> , 2016, 61, S152.	1.3	0
121	Stone extraction with loop ureteral catheter versus ureteroscopy in small distal ureteral stones – retrospective comparison of 547 consecutive patients. <i>Translational Andrology and Urology</i> , 2021, 10, 87-95.	0.6	0
122	Urachus- und Adenokarzinom der Harnblase. <i>Springer Reference Medizin</i> , 2021, , 1-9.	0.0	0
123	Retrograde Pyelography in the Presence of Urothelial Bladder Cancer Does Not Affect the Risk of Upper Tract Urothelial Cancer: A Retrospective Analysis of a Single-Centre Cohort. <i>Urologia Internationalis</i> , 2022, 106, 638-643.	0.6	0
124	Commentary: Treatment Outcome of Different Chemotherapy in Patients With Relapsed or Metastatic Malignant Urachal Tumor. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0